Prognostic Value of Hematologic Indices and Composite Models in Anal Squamous Cell Carcinoma Treated with Image-Guided Chemoradiotherapy
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10506803" target="_blank" >RIV/00064165:_____/25:10506803 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/25:10506803
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NJMxJJExPT" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NJMxJJExPT</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers17233838" target="_blank" >10.3390/cancers17233838</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Prognostic Value of Hematologic Indices and Composite Models in Anal Squamous Cell Carcinoma Treated with Image-Guided Chemoradiotherapy
Popis výsledku v původním jazyce
Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy primarily treated with chemoradiotherapy (CRT). This study evaluated outcomes and the prognostic value of simple hematologic indices in patients receiving modern image-guided CRT. Methods: Fifty-five patients with non-metastatic ASCC treated between 2017 and 2025 were retrospectively analyzed. Survival was estimated by Kaplan-Meier methods, and prognostic factors were assessed by log-rank testing and Cox regression. Baseline neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios were analyzed individually and in combination with nodal status. Results: At a median follow-up of 53.1 months, overall survival reached 90% at 5 years, whereas disease-free survival declined to 51%. Nodal positivity showed a non-significant trend toward poorer DFS. Baseline PLR >= 150 was significantly associated with inferior DFS in univariable analysis (HR 5.28, 95% CI 1.12-24.97, p = 0.036), while NLR >= 3 showed a borderline effect (p = 0.108). In multivariable models, PLR retained borderline prognostic relevance (p = 0.083), whereas Kaplan-Meier curves indicated non-significant trends (p = 0.129 and 0.055). Integrated models combining nodal status with PLR +/- NLR improved risk discrimination: Model A (N + PLR >= 150 +/- NLR >= 3) showed a trend (p = 0.059), and Model B (N + PLR >= 150) reached significance (p = 0.021; C-index approximate to 0.68-0.69). Conclusions: Modern CRT achieved excellent OS with acceptable toxicity, though early recurrences limited DFS. Integrating hematologic indices with nodal status provides a pragmatic, cost-effective approach for individualized risk assessment and follow-up in ASCC.
Název v anglickém jazyce
Prognostic Value of Hematologic Indices and Composite Models in Anal Squamous Cell Carcinoma Treated with Image-Guided Chemoradiotherapy
Popis výsledku anglicky
Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy primarily treated with chemoradiotherapy (CRT). This study evaluated outcomes and the prognostic value of simple hematologic indices in patients receiving modern image-guided CRT. Methods: Fifty-five patients with non-metastatic ASCC treated between 2017 and 2025 were retrospectively analyzed. Survival was estimated by Kaplan-Meier methods, and prognostic factors were assessed by log-rank testing and Cox regression. Baseline neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios were analyzed individually and in combination with nodal status. Results: At a median follow-up of 53.1 months, overall survival reached 90% at 5 years, whereas disease-free survival declined to 51%. Nodal positivity showed a non-significant trend toward poorer DFS. Baseline PLR >= 150 was significantly associated with inferior DFS in univariable analysis (HR 5.28, 95% CI 1.12-24.97, p = 0.036), while NLR >= 3 showed a borderline effect (p = 0.108). In multivariable models, PLR retained borderline prognostic relevance (p = 0.083), whereas Kaplan-Meier curves indicated non-significant trends (p = 0.129 and 0.055). Integrated models combining nodal status with PLR +/- NLR improved risk discrimination: Model A (N + PLR >= 150 +/- NLR >= 3) showed a trend (p = 0.059), and Model B (N + PLR >= 150) reached significance (p = 0.021; C-index approximate to 0.68-0.69). Conclusions: Modern CRT achieved excellent OS with acceptable toxicity, though early recurrences limited DFS. Integrating hematologic indices with nodal status provides a pragmatic, cost-effective approach for individualized risk assessment and follow-up in ASCC.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Cancers
ISSN
2072-6694
e-ISSN
2072-6694
Svazek periodika
17
Číslo periodika v rámci svazku
23
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
21
Strana od-do
3838
Kód UT WoS článku
001634233700001
EID výsledku v databázi Scopus
2-s2.0-105024484611